News

Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

Novadip and Cliniques universitaires Saint-Luc report positive results for compassionate use of NVD003 on four pediatric patients

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, and the Cliniques universitaires Saint-Luc have announced the successful treatment of four pediatric patients with Congenital Pseudarthrosis of the Tibia (CPT) using NVD003, an autologous therapy developed by Novadip for the reconstruction of bone tissue. CPT is a very

Read More
Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Novadip receives RMAT designation for NVD003, its regenerative treatment for congenital pseudarthosis of the tibia

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its tissue regeneration product, NVD003, for the treatment of congenital pseudarthosis of the tibia (CPT). The RMAT designation, issued to cell therapies, therapeutic tissue

Read More
Resolve Therapeutics and Duke Medical School initiate observational study of cell-free RNA in polytrauma patients

Resolve Therapeutics and Duke Medical School initiate observational study of cell-free RNA in polytrauma patients

Resolve Therapeutics, a leader in the emerging field of cell-free nucleic acid therapeutics, has announced a collaboration with the Department of Surgery, Duke University School of Medicine to analyze the role of cell-free RNA (cfRNA) in polytrauma. A significant number of trauma patients admitted to the hospital each year suffer

Read More
Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

Novadip releases five-year follow-up results for NVD003, regenerative treatment for severe bone non-union of lower limb

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the five-year follow-up results from the Phase 1/2 clinical trial of its investigational tissue regeneration product, NVD003, in adult patients with severe bone non-union (BNU) of the lower limb, following trauma. The five-year safety and efficacy data

Read More
VUV Analytics introduces HYDRA™: A breakthrough Vacuum Ultraviolet Detector for Liquid Chromatography

VUV Analytics introduces HYDRA™: A breakthrough Vacuum Ultraviolet Detector for Liquid Chromatography

VUV Analytics, Inc., a global leader in vacuum ultraviolet (VUV) spectroscopy, is excited to introduce HYDRA, a breakthrough detector for Liquid Chromatography (LC). HYDRA makes advanced chemical analysis easier with universal detection, exceptional spectral selectivity, and seamless integration into lab workflows. “HYDRA is a major step forward for Liquid Chromatography

Read More
Novadip appoints Soumya Chandramouli as Chief Financial Officer

Novadip appoints Soumya Chandramouli as Chief Financial Officer

Novadip Biosciences, a late-stage clinical biotechnology company specializing in regenerative medicine, has announced the appointment of Soumya Chandramouli as Chief Financial Officer (CFO). Soumya Chandramouli has 25 years’ experience in financial management, most recently as Chief Financial Officer of IBA Group, a listed company in the medical device and healthcare

Read More
San José City Council unanimously approves next phase of San José Airport Connector Project

San José City Council unanimously approves next phase of San José Airport Connector Project

San José Connection Partners, a consortium including Plenary Americas, Webcor/Obayashi, and HNTB, and Glydways has announced that the San José City Council voted unanimously to move the Diridon–Airport Connector into Phase 2a of project development. The decision marks a significant step toward achieving the City’s sustainable mobility goals, reflecting strong

Read More
NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology

NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology

NorthSea Therapeutics B.V. (‘NST’, or the ‘Company’), a private, late-stage clinical biotechnology company developing novel strategies to treat metabolic, cholestatic, and fibrotic diseases, has announced that results from the Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 metabolic dysfunction-associated steatohepatitis (MASH) were published in the Journal of Hepatology.

Read More
Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has announced that data from the Phase 2 trial of its TYK2 inhibitor VTX958 in Crohn’s disease will be presented during the 20th Congress of

Read More
Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio

Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio

Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases, has highlighted its 2025 pipeline strategy and provided clinical updates on its NLRP3 inhibitor portfolio, including VTX2735 and VTX3232. “We believe that 2025 will be

Read More
Phase Four Series C first closing

Phase Four Series C first closing

Phase Four, a leader in advanced in-space propulsion design and manufacturing, has announced the first close of its Series C funding round, securing nearly 60% of the target raise with strong participation from new and existing investors. The round is led by Artemis Group Capital, the Oklahoma-based investment firm helmed

Read More
VORAGO Technologies and Collabora partner to advance open source in space

VORAGO Technologies and Collabora partner to advance open source in space

VORAGO Technologies, a leading provider of radiation hardened and radiation tolerant MCUs and MPUs for Aerospace and Defense, and Collabora, a leader in open source software and support, today announced they are partnering to advance the use of open source to achieve resilience for mission critical applications in space. “As

Read More